glycolytic

BAY-876 是一种葡萄糖转运蛋白 1 (GLUT1) 抑制剂 (IC50=2 nM)，具有口服活性和选择性。BAY-876 对 GLUT1 选择性比 GLUT2、GLUT3 和 GLUT4 高 100 倍以上。BAY-876 抑制糖酵解代谢，具有抗肿瘤活性。

VLX600 是一种铁螯合氧化磷酸化抑制剂，是一种细胞渗透性抗癌剂。它通过减少肿瘤细胞中的线粒体氧化磷酸化起作用。

hydrocotarnine 是 Cbl 的抑制剂。

Lonidamine (Diclondazolic Acid) 是一种抗肿瘤药物，是己糖激酶、线粒体丙酮酸载体和质膜单羧酸转运蛋白抑制剂，同时也抑制线粒体复合物 II。

D-Fructose-6-phosphate (sodium salt hydrate) 是由磷酸葡萄糖异构酶将 6-磷酸葡萄糖异构化产生的糖酵解途径的糖中间体，可用于研究癌症。

2-Deoxy-D-galactose 是一种葡萄糖类似物，也是葡萄糖拮抗剂，抑制海马 LTP 的维持，能通过抑制糖酵解过程来抑止肿瘤生长。

VER-246608 是ATP 竞争性的丙酮酸脱氢酶激酶抑制剂，对PDK-1，PDK-3，PDK-2，和PDK-4的IC50分别为 35 nM，40 nM，84 nM 和 91 nM。

Glycogen, Mussel 是一种糖酵解的中间产物和高能磷酸盐，它是人类、动物、真菌和细菌的一种能量储存形式。

Phosphofructokinase 在糖酵解路径中扮演关键角色，负责催化果糖-6-磷酸转化为果糖-1,6-二磷酸。该酶的活性可通过 Phosphoenolpyruvate (PEP) 与果糖-6-磷酸的相互作用受到抑制，进而影响糖酵解过程的速度。此外，Phosphofructokinase 还可应用于测定果糖-6-磷酸 (fructose-6-phosphate) 的含量。

Lon-TK 是一种 LTB 的糖酵解抑制剂与 linker 的偶联物。LTB 是通过硫代缩酮 (thioketal) 连接的 Lonidamine (Lon) 和 PD-L1 抑制剂 (BMS-1) 的前药，能够有效地抑制肿瘤细胞的糖酵解代谢，同时阻断 PD-1 PD-L1 的免疫逃逸路径。Lon-TK 具有光动力增强免疫研究的潜在应用前景。

Dactylarin is a cytotoxic antibiotic. Dactylarin isolated from Dactylaria lutea. Dactylarin interacts with thiols, which explains its inhibitory effect on the above glycolytic enzymes.

SF2312 是一种由放线菌微孢子菌产生的天然膦酸盐抗生素，是高效的糖酵解酶烯醇化酶抑制剂。SF2312 具有抗菌活性，可抑制细菌生长，对革兰氏阴性和革兰氏阴性菌均具有抑制作用。SF2312 抑制人重组 ENO1 和 ENO2。

2-deoxy-D-Glucose-13C6is intended for use as an internal standard for the quantification of 2-deoxy-D-glucose by GC- or LC-MS. 2-deoxy-D-Glucose is a glucose antimetabolite and an inhibitor of glycolysis.1,2It inhibits hexokinase, the enzyme that converts glucose to glucose-6-phosphate, as well as phosphoglucose isomerase, the enzyme that converts glucose-6-phosphate to fructose-6-phosphate.32-deoxy-D-Glucose (16 mM) induces apoptosis in SK-BR-3 cells, as well as inhibits the growth of 143B osteosarcoma cells cultured under hypoxic conditions when used at a concentration of 2 mg ml.4,5In vivo, 2-deoxy-D-glucose (500 mg kg) reduces tumor growth in 143B osteosarcoma and MV522 non-small cell lung cancer mouse xenograft models when used alone or in combination with doxorubicin or paclitaxel .6 1.Kang, H.T., and Hwang, E.S.2-Deoxyglucose: An anticancer and antiviral therapeutic, but not any more a low glucose mimeticLife Sci.78(12)1392-1399(2006) 2.Aft, R.L., Zhang, F.W., and Gius, D.Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: Mechanism of cell deathBr. J. Cancer87(7)805-812(2002) 3.Ralser, M., Wamelink, M.M., Struys, E.A., et al.A catabolic block does not sufficiently explain how 2-deoxy-D-glucose inhibits cell growthProc. Natl. Acad. Sci. USA105(46)17807-17811(2008) 4.Liu, H., Savaraj, N., Priebe, W., et al.Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: A strategy for solid tumor therapy (Model C)Biochem. Pharmacol.64(12)1745-1751(2002) 5.Zhang, X.D., Deslandes, E., Villedieu, M., et al.Effect of 2-deoxy-D-glucose on various malignant cell lines in vitroAnticancer Res.26(5A)3561-3566(2006) 6.Maschek, G., Savaraj, N., Priebe, W., et al.2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivoCancer Res.64(1)31-34(2004)

CC260 is a selective PI5P4Kα and PI5P4Kβ inhibitor with Kis of 40 nM and 30 nM, respectively. CC260 does not inhibit or weakly inhibits other protein kinases, such as Plk1 and RSK2. CC260 can be used for cell energy metabolism, diabetes and cancer research[1]. In cultured C2C12 myotubes, CC260 (20 μM) enhances Insulin-induced Akt phosphorylation at both Thr-308 and Ser-473 but suppresses S6K phosphorylation (Thr-389) by mTORC1[1]. CC260 (2.5 μM, 5 μM, 10 μM, 20 μM) significantly increases phosphorylation of acetyl-CoA carboxylase (ACC) in a dose-dependent manner[1]. CC260 treatment reduces the ability of BT474 cells to survive serum starvation, which could be rescued by expressing the PI5P4Kβ refractory mutant[1]. In BT474 cells, CC260 treatment causes an increase in glycolytic ATP production[1]. [1]. Song Chen, et al. Pharmacological inhibition of PI5P4Kα β disrupts cell energy metabolism and selectively kills p53- tumor cells. Proc Natl Acad Sci U S A. 2021 May 25;118(21):e2002486118.

Pomhex 是一种具有抗癌活性的细胞渗透性强效烯醇化酶抑制剂，可用于癌症致死率的研究。Pomhex是一种外消旋混合物，是一种强效且具有选择性的ENO2抑制剂。

1,2,3-Trioctanoyl-rac-glycerol-13C3 is intended for use as an internal standard for the quantification of 1,2,3-trioctanoyl-rac-glycerol by GC- or LC-MS. 1,2,3-Trioctanoyl-rac-glycerol is a triacylglycerol that contains octanoic acid at the sn-1, sn-2, and sn-3 positions. Dietary administration of 1,2,3-trioctanoyl-rac-glycerol increases hippocampal levels of the glycolytic metabolites glucose 6-phosphate, fructose 6-phosphate, and β-hydroxybutyrate and the seizure threshold in the 6 Hz psychomotor seizure test in mice.1 Formulations containing 1,2,3-trioctanoyl-rac-glycerol have been used in cosmetic products as thickening and skin-conditioning agents.

CBR-470-1 是一种有效的糖酵解磷酸甘油酸激酶1 (PGK1) 抑制剂，通过增加甲基乙二醛的水平来激活 NRF2。 CBR-470-1 是一种非共价的 Nrf2 激活剂，具有神经保护活性，通过激活 Keap1-Nrf2 级联反应来保护 SH-SY5Y 神经元细胞免受 MPP+ 诱导的细胞毒性。

D-Fructose-6-phosphate disodium salt (D-FRUCTOSE 6-PHOSPHATE DISODIUM SALT) 是内源性代谢产物的一种。

MOPIPP 是新型的吲哚基查尔酮，可以透过血脑屏障。MOPIPP 对胶质母瘤细胞的肿瘤进展有抑制作用。MOPIPP 诱导细胞空泡化并增加自噬体数量。MOPIPP 还会触发细胞巨泡式死亡，并且中断葡萄糖摄取和糖酵解代谢。

PKM2 activator 2是一种丙酮酸激酶 M2（PKM2）激活剂，AC 50 值为 66 nM。PKM2 activator 2具有抗肿瘤增殖和缓解沃伯格效应的作用，通过激活 PKM2 使细胞的糖酵解代谢恢复正常。

NCI-006 is a potent new inhibitor of lactate dehydrogenase (LDH) that disrupts tumor growth in mice. LDH inhibition slows tumor growth but rapidly redirects pyruvate to support mitochondrial metabolism. Inhibiting both mitochondrial complex 1 and LDH suppresses metabolic plasticity of glycolytic tumors in vivo, significantly prolonging tumor growth inhibition.

Ellipyrone A为一种大环肽，对二肽基肽酶 4 (dipeptidyl peptidase-4: IC50=0.35 mM) 显示出抑制活性，并对α-葡萄糖苷酶 (IC50=0.74 mM) 及α-淀粉酶 (IC50=0.59 mM) 也具有明显的抑制效果，表现出其抗碳水化合物分解的性能。

Aldolase 是一种糖酵解酶，也是 vATP 酶复合物的组成部分。Aldolase 可使 1，6-二磷酸果糖分解成二羟基丙酮和 3-磷酸甘油醛。

Hexokinase(ScHEX1) 是一种糖酵解酶己糖激酶，收到 N-乙酰氨基葡萄糖的抑制。N-乙酰氨基葡萄糖对 Hexokinase(ScHEX1) 的抑制导致其与线粒体外膜分离，而导致 NLRP3炎症小体激活。